Thrombolysis in submassive pulmonary embolism

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 8, 2004, Pages 1473-1474

  Goldhaber, S Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; PLACEBO; STREPTOKINASE; UROKINASE;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; STROKE; SYSTEMIC DISEASE; TREATMENT OUTCOME;

EID: 13244273428     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00706.x     Document Type: Article

References (36)

1. Konstantinides S. Thrombolysis in submassive pulmonary embolism? Yes. J Thromb Haemost 2003; 1: 1127-9.
2. Dalen JE. Thrombolysis in submassive pulmonary embolism? No. J Thromb Haemost. 2003; 1: 1130-2.
3. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003; 349: 1695-702.
4. Goldhaber SZ. Echocardiography in the management of pulmonary embolism. Ann Intern Med. 2002; 136: 691-700.
5. Kucher N & Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108: 2191-4.
6. The Urokinase Pulmonary Embolism Thrombolysis Study Group. The Urokinase pulmonary embolism trial. Morbidity Mortality Circulation 1973; 17-18: 66-72.
7. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism. Right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134: 479-87.
8. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, Conti A, Agnelli G, Berni G. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817-22.
9. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, Iversen S, Redecker M, Kienast J, Just H, Kasper W. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry [see comments]. Circulation 1997; 96: 882-8.
10. Hamel E, Pacouret G, Vincentelli D, Forissier JF, Peycher P, Pottier JM, Charbonnier B. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001; 120: 120-5.
11. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-50.
12. Dalen JE. Thrombolysis in submassive pulmonary embolism? No. J Thromb Haemost 2003; 1: 1130-2.
13. Konstantinides S. Thrombolysis in submassive pulmonary embolism? Yes. J Thromb Haemost 2003; 1: 1127-9.
14. Levine MN, Goldhaber SZ, Gore JM, Hirsh J, Califf RM. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995; 108: 291S-301S.
15. Perrier A, Nendaz MR, Sarasin FP, Howarth N, Bounameaux H. Cost-effectiveness of diagnostic strategies for suspected pulmonary embolism including helical computed tomography. Am J Respir Crit Care Med 2003; 167: 39-44.
16. Konstantinides S. Thrombolysis in submassive pulmonary embolism? Yes. J Thromb Haemost 2003; 1: 1127-9.
17. Dalen JE. Thrombolysis in submassive pulmonary embolism? No. J Thromb Haemost 2003; 1: 1130-2.
18. Task Force on Pulmonary Embolism European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000; 21: 1301-36.
19. Kurzyna M, Torbicki A, Pruszczyk P, Burakowska B, Fijalkowska A, Kober J, Oniszh K, Kuca P, Tomkowski W, Burakowski J, Wawrzynska L. Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol 2002; 90: 507-11.
20. Pruszczyk P, Bochowicz A, Kostrubiec M, Torbicki A, Szulc M, Gurba H, Kuczynska K, Berent H. Myoglobin stratifies short-term risk in acute major pulmonary embolism. Clin Chim Acta 2003; 338: 53-6.
21. Pruszczyk P, Kostrubiec M, Bochowicz A, Styczynski G, Szulc M, Kurzyna M, Fijalkowska A, Kuch-Wocial A, Chlewicka I, Torbicki A. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22: 649-53.
22. Pruszczyk P, Bochowicz A, Torbicki A, Szulc M, Kurzyna M, Fijalkowska A, Kuch-Wocial A. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003; 123: 1947-52.
23. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzynska L. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-8.
24. Torbicki A, Galie N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ; ICOPER Study Group. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003; 41: 2245-51.
25. Tomkowski W, Borowiec B, Kober J, Filipecki S, Wiecheka A, Pawlicka L. [Very low doses of tissue plasminogen activator in treatment of acute massive pulmonary embolism]. Pneumonol Alergol Pol 1996; 64 (Suppl. 2): 207-10.
26. Ding BS, Zhou YJ, Chen XY, Zhang J, Zhang PX, Sun ZY, Tan XY, Liu JN. Lung endothelium targeting for pulmonary embolism thrombolysis. Circulation 2003; 108: 2892-8.
27. Konstantinides S. Thrombolysis in submassive pulmonary embolism? Yes. J Thromb Haemost 2003; 1: 1127-9.
28. Dalen JE. Thrombolysis in submassive pulmonary embolism? No. J Thromb Haemost 2003; 1: 1130-2.
29. Kasper W, Kostantinidis S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-9.
30. Giannitsis E, Muller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, Katus AH. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211-7.
31. ten Wolde M, Tulevski II, Mulder JW, Sohne M, Boomsma F, Mulder BJ, Buller HR. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-4.
32. Grifoni S, Olivotto I, Ceechini P, Pieralli F, Camaiti A, Santoro G, Conti A, Agnelli G, Berni G. Short term clinical outcome of patients with pulmonary embolism, normal blood pressure and echocardiographycal right ventricular dysfunction. Circulation 2000; 101: 2817-216.33.
33. Konstantinindes S, Geibel A, Heusel G, Heinrich F, Kasper W for the Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism. N Eng J Med 2002; 347: 1143-50.
34. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA, Mogtader A, McDonough TJ, Braunwald E. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing RV function and pulmonary perfusion. Lancet 1993; 341: 507-11.
35. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002; 162: 2537-41.
36. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO I trial. Circulation 1995; 92: 2811-8.